Biotech Startups in India

How India's biotech startups are funded and supported, why biotech is a hard business for young firms, and where new opportunities lie.

India’s startup boom has extended into biotechnology: new companies working on diagnostics, vaccines, medical devices, agricultural biotech and new drugs.

Support systems

BIRAC, the Biotechnology Industry Research Assistance Council, set up in 2012 by the Department of Biotechnology, funds early-stage biotech ideas through grants and incubators.
Incubators at institutions like IITs and research centres provide lab space.
The BioE3 policy, approved in 2024, promotes biomanufacturing.

Why biotech is hard

Long timelines: years before revenue.
High capital needs for labs and trials.
Regulatory complexity.
Scarce specialised investors compared with software.

Opportunities

Diagnostics: low-cost testing kits, which boomed during COVID-19.
Medical devices for Indian conditions.
Biosimilars and vaccines.
Agricultural biotech and biomanufacturing.

Funding gap

Biotech needs patient capital. Many Indian biotech startups rely on grants early and struggle to raise later rounds. Some partner with large companies or license their technologies abroad.

The test kit

A small Pune startup develops a low-cost diagnostic kit with a BIRAC grant. During the pandemic, it scales up rapidly, showing how frugal biotech innovation can meet urgent needs.

Thinking biotech startups work like software startups

Biotech needs more money, time and regulatory approval before earning revenue.

Key takeaways

India's biotech startups work in diagnostics, devices, vaccines and more.
BIRAC (2012) funds early-stage biotech innovation.
Long timelines and high capital needs make biotech hard.
Patient capital and partnerships help bridge funding gaps.